Indeed, the relapse in B-ALL patients following CD19 CAR-T treatment can affect even half of them, but the cumulative incidence of relapse according to the meta-analysis of available clinical trials’ reports is estimated at 36% [90]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.